Boan Biotech (6955.HK) today announced its 2023 financial results and latest developments.High-quality development delivering remarkable performanceDuring the reporting period, the company's reven...
A symposium called the New Treatment Paradigm for Small Cell Lung Cancer (SCLC) organized by the Hong Kong Cancer Therapy Society (HKCTS) with support from Luye Pharma Group (Luye Pharma) took place i...
Boan Biotech announced today that it has received GMP certification from the Brazilian Agência Nacional de Vigilância Sanitária (ANVISA) for its biological product, Boyuno®(Bevacizu...
December 27, 2023 -- Boan Biotech today announced that two of its Claudin18.2-targeted investigational drugs have been granted the Orphan Drug Designation (ODD) for the treatment of pancreatic cancer ...
December 13, 2023– Luye Pharma Group today announced that two of its in-house developed innovative formulations have been included on the National Reimbursement Drug List for Basic Medical Insur...
December 13, 2023 -- Luye Diagnostics Group today announced that Great Basin Toxigenic C. difficile Direct Test (CDF2), independently developed by Vela Operations USA, has been approved by U.S. Food a...
Lurbinectedin is a new chemical compound with a novel mechanism of action. It’s been the only new chemical entity approved by the U.S. FDA for the treatment of relapsed SCLC over the past 26 yea...
The 6th China International Import Expo (CIIE) kicked off on November 5th, 2023. With its spillover effect, the CIIE provides a major platform for the internationalization of Traditional Chinese Medic...
Shanghai, October 31, 2023 -- Luye Pharma Group today announced that its exclusive new drug, Rivastigmine Twice Weekly Transdermal Patch, has been approved by China's National Medical Products Adm...
Shanghai, October 9, 2023 - Luye Pharma Group today announced the submission of the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) through the 505(b)(2) pathway for its LY03...
TOP